Results for FAERS

Publications & Outputs

1. Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system

   Li, C., Ding, Y., Cai, S., Liu, B. C. & Wang, X., 26/05/2025, In: Frontiers in Immunology. 16, 1596842.

   Research output: Contribution to Journal/Magazine › Journal article › peer-review